Eiken

  • Site Map
  • Contact Us
  • En|Jp
  • About Eiken
  • Products
  • Our Fields
  • Publication
  • Investor Relations
  • Research and Development
  • Sustainability

About Us

About Us

  • Message from the CEO
  • Our Management Philosophy
  • Brand Story
  • Our Business
  • Company Profile
  • Offices/Group Company
  • Executives
  • Eiken's History
  • Management Plan
  • PR Videos

Products

Products

  • Fecal Testing "OC-SENSOR"
  • Molecular Test “LAMP”
  • Culture Media
  • Immunological and Serological Reagents “LZ Test Eiken”
  • Rapid Testing
  • Veterinary “VET-SAA Eiken”

Our Fields

Our Fields

  • Gastroenterology
  • Infectious diseases
  • Veterinary

Publication

Publication

  • Fecal Immunochemical Test
  • Gastric Cancer Risk Assessment Test (ABCD risk classification)
  • Veterinary
  • Molecular Test "LAMP"

Investor Relations

Investor Relations

  • Message form the CEO
  • Management Plan
  • Financial Data or Financial Highlites
  • IR Library
  • Stakeholder Message
  • Stock Information
  • IR Calender
  • IR News
  • IR Policy
  • Operating Risks

Research and Development

Research and Development

  • R&D Vision
  • EIKEN’s Technologies
  • R&D Structure
  • Intellectual Property

Sustainability

Sustainability

  • CEO Message
  • Eiken and Sustainability
  • ESG Data
  • Integrated Report
  • Stakeholder Message
  • External Evaluation

Medical

  • Improving Access to Healthcare
  • Solutions to Medical Issues
  • Pursuing Quality and Establishing Sustainable Supply Chains

Environment

  • Environmental Management
  • Responding to Climate Change
  • Contributing to a Recycling-Oriented Society

Social

  • Respecting Human Rights and Diversity
  • Employee Engagement and Personnel Training
  • Boosting Health and Ensuring Safety and Hygiene

Governance

  • Achieving Transparent and Sound Governance
  • Rigorous Compliance and Thorough Corruption Prevention
  • Establishing Risk Management
  • En
  • Jp
Investor RelationsInvestor Relations

Investor Relations

  1. TOP
  2. Investor Relations
  3. Stakeholder Message

Stakeholder Message

Professor Graeme P. Young AM FTSE FAHMS FGESA AGAF

・Biography
・Global status of colorectal cancer
・The effectiveness of FIT
・What is required of a FIT when screening for colorectal cancer
・Conclusions
・References

Detail

Dr. Shigeru Omi

・Tuberculosis: environment and issues
・Significance of the LAMP method and the role it fulfills
・Expectations for the LAMP method going forward

Detail

Management
policy

  • Message form the CEO
  • Management Plan
  • Operating Risks
  • Corporate Governance

IR Library

  • Financial Statements
  • Annual Securities Report
  • IR Reports
  • Presentations

Stock
Information

  • Stock Information
  • Shareholder Return
  • Stock Price
  • Analyst Coverage
Financial Highlights
-consolidated-
  • IR Calender
  • IR Policy
  • IR News
  • Contact us
  • News
  • Site Map
  • Term of Use
  • Privacy Policy

Copyright(C) Eiken Chemical Co., Ltd. All Rights Reserved.

Eiken

We use cookies to improve your online experience of this website.
If you continue to browse without changing your settings, we will assume that you are agreeing to our use of cookies.
You can also click the "Agree" button to accept our policy, then this message does not appear in the future.
Full details are in our Privacy Policy.

Agree